Literature DB >> 21976642

The C-terminal region of lymphocytic choriomeningitis virus nucleoprotein contains distinct and segregable functional domains involved in NP-Z interaction and counteraction of the type I interferon response.

Emilio Ortiz-Riaño1, Benson Yee Hin Cheng, Juan Carlos de la Torre, Luis Martínez-Sobrido.   

Abstract

Several arenaviruses cause hemorrhagic fever (HF) disease in humans that is associated with high morbidity and significant mortality. Arenavirus nucleoprotein (NP), the most abundant viral protein in infected cells and virions, encapsidates the viral genome RNA, and this NP-RNA complex, together with the viral L polymerase, forms the viral ribonucleoprotein (vRNP) that directs viral RNA replication and gene transcription. Formation of infectious arenavirus progeny requires packaging of vRNPs into budding particles, a process in which arenavirus matrix-like protein (Z) plays a central role. In the present study, we have characterized the NP-Z interaction for the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). The LCMV NP domain that interacted with Z overlapped with a previously documented C-terminal domain that counteracts the host type I interferon (IFN) response. However, we found that single amino acid mutations that affect the anti-IFN function of LCMV NP did not disrupt the NP-Z interaction, suggesting that within the C-terminal region of NP different amino acid residues critically contribute to these two distinct and segregable NP functions. A similar NP-Z interaction was confirmed for the HF arenavirus Lassa virus (LASV). Notably, LCMV NP interacted similarly with both LCMV Z and LASV Z, while LASV NP interacted only with LASV Z. Our results also suggest the presence of a conserved protein domain within NP but with specific amino acid residues playing key roles in determining the specificity of NP-Z interaction that may influence the viability of reassortant arenaviruses. In addition, this NP-Z interaction represents a potential target for the development of antiviral drugs to combat human-pathogenic arenaviruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21976642      PMCID: PMC3233175          DOI: 10.1128/JVI.05834-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles.

Authors:  Ki Jeong Lee; Mar Perez; Daniel D Pinschewer; Juan Carlos de la Torre
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 2.  Arenaviruses other than Lassa virus.

Authors:  Rémi N Charrel; Xavier de Lamballerie
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 5.970

3.  Simultaneous visualization of multiple protein interactions in living cells using multicolor fluorescence complementation analysis.

Authors:  Chang-Deng Hu; Tom K Kerppola
Journal:  Nat Biotechnol       Date:  2003-04-14       Impact factor: 54.908

4.  Transmission of lymphocytic choriomeningitis virus by organ transplantation.

Authors:  Staci A Fischer; Mary Beth Graham; Matthew J Kuehnert; Camille N Kotton; Arjun Srinivasan; Francisco M Marty; James A Comer; Jeannette Guarner; Christopher D Paddock; Dawn L DeMeo; Wun-Ju Shieh; Bobbie R Erickson; Utpala Bandy; Alfred DeMaria; Jeffrey P Davis; Francis L Delmonico; Boris Pavlin; Anna Likos; Martin J Vincent; Tara K Sealy; Cynthia S Goldsmith; Daniel B Jernigan; Pierre E Rollin; Michelle M Packard; Mitesh Patel; Courtney Rowland; Rita F Helfand; Stuart T Nichol; Jay A Fishman; Thomas Ksiazek; Sherif R Zaki
Journal:  N Engl J Med       Date:  2006-05-25       Impact factor: 91.245

5.  Characterization of polypeptides immunoprecipitable from Pichinde virus-infected BHK-21 cells.

Authors:  D G Harnish; W C Leung; W E Rawls
Journal:  J Virol       Date:  1981-06       Impact factor: 5.103

6.  Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis.

Authors:  M B Mets; L L Barton; A S Khan; T G Ksiazek
Journal:  Am J Ophthalmol       Date:  2000-08       Impact factor: 5.258

7.  Mechanism of lymphocytic choriomeningitis virus entry into cells.

Authors:  P Borrow; M B Oldstone
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

8.  Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP).

Authors:  Robert Eichler; Thomas Strecker; Larissa Kolesnikova; Jan ter Meulen; Winfried Weissenhorn; Stephan Becker; Hans Dieter Klenk; Wolfgang Garten; Oliver Lenz
Journal:  Virus Res       Date:  2004-03-15       Impact factor: 3.303

9.  A new arenavirus in a cluster of fatal transplant-associated diseases.

Authors:  Gustavo Palacios; Julian Druce; Lei Du; Thomas Tran; Chris Birch; Thomas Briese; Sean Conlan; Phenix-Lan Quan; Jeffrey Hui; John Marshall; Jan Fredrik Simons; Michael Egholm; Christopher D Paddock; Wun-Ju Shieh; Cynthia S Goldsmith; Sherif R Zaki; Mike Catton; W Ian Lipkin
Journal:  N Engl J Med       Date:  2008-02-06       Impact factor: 91.245

10.  The role of myristoylation in the membrane association of the Lassa virus matrix protein Z.

Authors:  Thomas Strecker; Anna Maisa; Stephane Daffis; Robert Eichler; Oliver Lenz; Wolfgang Garten
Journal:  Virol J       Date:  2006-11-05       Impact factor: 4.099

View more
  34 in total

1.  Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε.

Authors:  Christelle Pythoud; W W Shanaka I Rodrigo; Giulia Pasqual; Sylvia Rothenberger; Luis Martínez-Sobrido; Juan Carlos de la Torre; Stefan Kunz
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

3.  Arenavirus nucleoproteins prevent activation of nuclear factor kappa B.

Authors:  W W Shanaka I Rodrigo; Emilio Ortiz-Riaño; Christelle Pythoud; Stefan Kunz; Juan C de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  Development of live-attenuated arenavirus vaccines based on codon deoptimization.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Aitor Nogales; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

5.  Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.

Authors:  Benson Y H Cheng; Aitor Nogales; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  Virology       Date:  2016-11-14       Impact factor: 3.616

6.  The use of novel epitope-tagged arenaviruses reveals that Rab5c-positive endosomal membranes are targeted by the LCMV matrix protein.

Authors:  Christopher M Ziegler; Emily A Bruce; Jamie A Kelly; Benjamin R King; Jason W Botten
Journal:  J Gen Virol       Date:  2018-02       Impact factor: 3.891

7.  A Highly Conserved Leucine in Mammarenavirus Matrix Z Protein Is Required for Z Interaction with the Virus L Polymerase and Z Stability in Cells Harboring an Active Viral Ribonucleoprotein.

Authors:  Masaharu Iwasaki; Juan C de la Torre
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

8.  Cleavage of the Junin virus nucleoprotein serves a decoy function to inhibit the induction of apoptosis during infection.

Authors:  Svenja Wolff; Stephan Becker; Allison Groseth
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor.

Authors:  Emilio Ortiz-Riaño; Nhi Ngo; Stefanie Devito; Dirk Eggink; Joshua Munger; Megan L Shaw; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

10.  Influenza A and B virus intertypic reassortment through compatible viral packaging signals.

Authors:  Steven F Baker; Aitor Nogales; Courtney Finch; Kevin M Tuffy; William Domm; Daniel R Perez; David J Topham; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.